Challenges, opportunities and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 - 2023)
{{output}}
Introduction: Since the approval of the first JAK inhibitor, ruxolitinib, in 2011, the development of JAK inhibitors has expanded significantly, with applications spanning autoimmune diseases, cancer, and inflammatory disorders. ... ...
